July 2021
1. STEINBROOK R
   The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease.
   JAMA Intern Med. 2021 Jul 13. pii: 2782122. doi: 10.1001/jamainternmed.2021.4622
   

   >> Share

   
   
2. DUNN B, Stein P, Cavazzoni P
   Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective.
   JAMA Intern Med. 2021 Jul 13. pii: 2782119. doi: 10.1001/jamainternmed.2021.4607
   

   >> Share

   
   
3. MITCHELL SL, D'Agata EMC, Hanson LC, Loizeau AJ, et al
   The Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer Disease and Other Dementias (TRAIN-AD): A Cluster Randomized Clinical Trial.
   JAMA Intern Med. 2021 Jul 12. pii: 2782003. doi: 10.1001/jamainternmed.2021.3098
   

   >> Share

   
   November 2020
4. NICHOLAS LH, Langa KM, Bynum JPW, Hsu JW, et al
   Financial Presentation of Alzheimer Disease and Related Dementias.
   JAMA Intern Med. 2020 Nov 30. pii: 2773241. doi: 10.1001/jamainternmed.2020.6432
   

   >> Share

   
   December 2019
5. BURKE JF, Langa KM
   Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease-Reply.
   JAMA Intern Med. 2019;179:1737.
   

   >> Share

   
   
6. RABINOVICI GD, Carrillo MC
   Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease.
   JAMA Intern Med. 2019;179:1736-1737.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share